CO2020000260A2 - Anticuerpos quiméricos para el tratamiento de enfermedades de deposición del amiloide - Google Patents
Anticuerpos quiméricos para el tratamiento de enfermedades de deposición del amiloideInfo
- Publication number
- CO2020000260A2 CO2020000260A2 CONC2020/0000260A CO2020000260A CO2020000260A2 CO 2020000260 A2 CO2020000260 A2 CO 2020000260A2 CO 2020000260 A CO2020000260 A CO 2020000260A CO 2020000260 A2 CO2020000260 A2 CO 2020000260A2
- Authority
- CO
- Colombia
- Prior art keywords
- amyloid deposition
- treatment
- chimeric antibodies
- antibody
- deposition diseases
- Prior art date
Links
- 230000003941 amyloidogenesis Effects 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 239000000463 material Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
Abstract
Un anticuerpo humano de ratón quimérico para el tratamiento de las enfermedades de la deposición del amiloide, composiciones farmacéuticas que comprenden el anticuerpo, métodos y materiales para producir el anticuerpo y métodos para tratar la enfermedad de la deposición del amiloide usando el anticuerpo y la composición farmacéutica.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762526835P | 2017-06-29 | 2017-06-29 | |
PCT/US2018/039905 WO2019006062A1 (en) | 2017-06-29 | 2018-06-28 | CHIMERIC ANTIBODIES FOR THE TREATMENT OF AMYLOID DETECTION DISEASES |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2020000260A2 true CO2020000260A2 (es) | 2020-04-13 |
Family
ID=64743039
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2020/0000260A CO2020000260A2 (es) | 2017-06-29 | 2020-01-13 | Anticuerpos quiméricos para el tratamiento de enfermedades de deposición del amiloide |
Country Status (13)
Country | Link |
---|---|
US (2) | US11530257B2 (es) |
EP (1) | EP3624842A4 (es) |
JP (1) | JP2020526191A (es) |
KR (2) | KR102607629B1 (es) |
CN (2) | CN117924478A (es) |
AU (1) | AU2018290898B2 (es) |
BR (1) | BR112019028149A2 (es) |
CA (1) | CA3067597C (es) |
CO (1) | CO2020000260A2 (es) |
IL (1) | IL271488B1 (es) |
MX (1) | MX2019015914A (es) |
RU (1) | RU2746325C1 (es) |
WO (1) | WO2019006062A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11382974B2 (en) * | 2017-08-01 | 2022-07-12 | The Trustees Of Columbia University In The City Of New York | Methods and compositions for treatment of amyloid deposition diseases |
EP3873932A4 (en) * | 2018-10-31 | 2022-11-23 | The Trustees Of Columbia University In The City Of New York | METHODS AND COMPOSITIONS FOR IMAGING AMYLOID DEPOSITS |
CA3158206A1 (en) * | 2019-11-15 | 2021-05-20 | Jonathan S. Wall | Modified immunoglobulins for targeting amyloid deposits cross-reference to related applications |
CN117004700A (zh) * | 2023-10-07 | 2023-11-07 | 北京爱博生生物技术有限公司 | 单克隆抗体可变区基因高通量测序的方法及其所用组合物与试剂盒 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030147882A1 (en) * | 1998-05-21 | 2003-08-07 | Alan Solomon | Methods for amyloid removal using anti-amyloid antibodies |
DK1078005T3 (da) * | 1998-05-21 | 2010-08-09 | Univ Tennessee Res Foundation | Fremgangsmåder til amyloidfjernelse ved anvendelse af anti-amyloidantistoffer |
UA81216C2 (en) | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
CN101670105B (zh) * | 2000-02-24 | 2014-08-06 | 华盛顿大学 | 螯合淀粉样蛋白β肽的人源化抗体 |
MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
MX2007000998A (es) | 2004-07-30 | 2007-07-11 | Rinat Neuroscience Corp | Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos. |
KR101413615B1 (ko) | 2006-03-23 | 2014-07-18 | 바이오악틱 뉴로사이언스 에이비 | 인간 프로토피브릴에 선택적인 개선된 항체 및 이의 용도 |
CN103539857A (zh) * | 2006-03-30 | 2014-01-29 | 葛兰素集团有限公司 | 针对β-淀粉样蛋白肽的抗体 |
AR062065A1 (es) | 2006-07-14 | 2008-10-15 | Ac Immune Sa | Anticuerpo humanizado |
AU2008299516B2 (en) | 2007-09-13 | 2013-09-12 | Delenex Therapeutics Ag | Humanized antibodies against the beta-amyloyd peptide |
NZ586875A (en) | 2007-12-28 | 2012-10-26 | Elan Pharm Inc | Treatment and prophylaxis of amyloidosis with an antibody that binds a specific epitope of human amyloid A peptide |
US8195594B1 (en) | 2008-02-29 | 2012-06-05 | Bryce thomas | Methods and systems for generating medical reports |
US20090297439A1 (en) | 2008-06-02 | 2009-12-03 | Metheresis Translational Research Sa, | Anti-met monoclonal antibody, fragments and derivatives thereof for use in tumor diagnosis, corresponding compositions and kits |
EA037797B1 (ru) | 2011-10-25 | 2021-05-21 | Протена Байосайенсиз Лимитед | Состав антитела, пригодный для профилактики и лечения амилоидоза, его варианты и способ его получения |
JP2017528449A (ja) * | 2014-08-26 | 2017-09-28 | ユニバーシティ オブ テネシー リサーチ ファウンデーション | アミロイドーシスのための標的化免疫療法 |
BR112017024877A2 (pt) | 2015-05-20 | 2019-09-17 | Janssen Biotech, Inc. | anticorpo anti-cd38 e seu uso no tratamento de amiloidose de cadeia leve e outras malignidades hematológicas positivas para cd38 |
US11382974B2 (en) * | 2017-08-01 | 2022-07-12 | The Trustees Of Columbia University In The City Of New York | Methods and compositions for treatment of amyloid deposition diseases |
-
2018
- 2018-06-28 MX MX2019015914A patent/MX2019015914A/es unknown
- 2018-06-28 US US16/626,613 patent/US11530257B2/en active Active
- 2018-06-28 EP EP18822805.0A patent/EP3624842A4/en active Pending
- 2018-06-28 CA CA3067597A patent/CA3067597C/en active Active
- 2018-06-28 IL IL271488A patent/IL271488B1/en unknown
- 2018-06-28 WO PCT/US2018/039905 patent/WO2019006062A1/en active Application Filing
- 2018-06-28 BR BR112019028149-5A patent/BR112019028149A2/pt unknown
- 2018-06-28 KR KR1020207002623A patent/KR102607629B1/ko active IP Right Grant
- 2018-06-28 RU RU2019141754A patent/RU2746325C1/ru active
- 2018-06-28 KR KR1020237040150A patent/KR20230164223A/ko active Application Filing
- 2018-06-28 JP JP2019572403A patent/JP2020526191A/ja active Pending
- 2018-06-28 CN CN202410121279.2A patent/CN117924478A/zh active Pending
- 2018-06-28 CN CN201880043888.3A patent/CN111093692A/zh active Pending
- 2018-06-28 AU AU2018290898A patent/AU2018290898B2/en active Active
-
2020
- 2020-01-13 CO CONC2020/0000260A patent/CO2020000260A2/es unknown
-
2022
- 2022-12-15 US US18/066,469 patent/US20230212273A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN117924478A (zh) | 2024-04-26 |
MX2019015914A (es) | 2020-08-06 |
WO2019006062A1 (en) | 2019-01-03 |
AU2018290898B2 (en) | 2021-03-11 |
KR102607629B1 (ko) | 2023-12-01 |
KR20230164223A (ko) | 2023-12-01 |
JP2020526191A (ja) | 2020-08-31 |
EP3624842A1 (en) | 2020-03-25 |
IL271488A (en) | 2020-02-27 |
CA3067597A1 (en) | 2019-01-03 |
RU2746325C1 (ru) | 2021-04-12 |
US11530257B2 (en) | 2022-12-20 |
US20200181246A1 (en) | 2020-06-11 |
CA3067597C (en) | 2023-03-21 |
IL271488B1 (en) | 2024-02-01 |
BR112019028149A2 (pt) | 2020-07-21 |
KR20200022479A (ko) | 2020-03-03 |
AU2018290898A1 (en) | 2020-01-16 |
CN111093692A (zh) | 2020-05-01 |
US20230212273A1 (en) | 2023-07-06 |
EP3624842A4 (en) | 2021-04-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2019000979A1 (es) | Composiciones y anticuerpos anti-lag-3. | |
CO2020000260A2 (es) | Anticuerpos quiméricos para el tratamiento de enfermedades de deposición del amiloide | |
CY1122840T1 (el) | Ανθρωποποιημενα ή χιμαιρικα αντισωματα cd3 | |
CO2017005784A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades | |
CO2017013356A2 (es) | Anticuerpos de factor xi | |
DOP2016000133A (es) | Anticuerpo pd-1, fragmento de unión al antígeno de este y uso médico de este | |
PE20161210A1 (es) | Anticuerpos anti-mcam y metodos de uso asociados | |
CO2017007121A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades | |
ECSP18096095A (es) | Anticuerpos a la alfa-sinucleína y usos de los mismos | |
MX2019011117A (es) | Anticuerpo b7-h3, fragmento de union a antigeno de los mismos y uso medico de los mismos. | |
UY36905A (es) | Anticuerpos neutralizantes de poliomavirus | |
CL2019000836A1 (es) | Construcciones de inmunoglobulina heterodiméricas y métodos de preparación de las mismas. | |
JOP20170004B1 (ar) | الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته | |
CO2019014286A2 (es) | Bis-octahidrofenantreno carboxamidas y conjugados de proteína de las mismas | |
CO2018001840A2 (es) | Composiciones biofarmacéuticas que comprenden anticuerpos anti-il-5 | |
CL2021002637A1 (es) | Anticuerpos y fragmentos de los mismos que se unen al receptor cannabinoide 1 (cb1) humano y métodos para antagonizar cb1 (divisional de la solicitud no. 201602433) | |
AR101740A1 (es) | Terapia de combinación y composiciones | |
CO2019007823A2 (es) | Anticuerpo anti-cd3 y moléculas que comprenden el anticuerpo | |
AR115583A1 (es) | Composiciones y métodos para el tratamiento de las enfermedades y trastornos del hígado | |
BR112017012381A2 (pt) | imunoterapia para doença angiogênica | |
CO2019007686A2 (es) | Anticuerpos anti-properdina monovalentes y fragmentos de anticuerpo | |
CO2017001087A2 (es) | Anticuerpos anti proteína similar a angiopoyetina 4 | |
EA201892265A1 (ru) | Способы лечения офтальмологических заболеваний | |
AR104755A1 (es) | Método para el tratamiento de enfermedad neurológica | |
UY36261A (es) | Anticuerpos anti proteína similar a angiopoyetina-4 (angptl4) y métodos de uso |